{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:08Z","timestamp":1787016968675,"version":"build-2736575974"},"reference-count":40,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,8,8]]},"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Subcutaneous tumour necrosis factor alpha TNF\u03b1inhibitors (SC-TNFis) such as golimumab (GLM), adalimumab (ADA), etanercept (ETA) and certolizumab pegol (CZP) have been used for many years for the treatment of inflammatory arthritis. Non-adherence to therapy is an important modifiable factor that may compromise patient outcomes. The aim of this analysis was to compare adherence and dosing interval of SC-TNFis in the treatment of people with inflammatory arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We used the IMS Brogan database combining both Canadian private and public drug plan databases of Ontario and Quebec. Target drugs included SC-TNFis for inflammatory arthritis. The index period was from 1 January 2010 to 30 June 2012 and patients were followed for 24 months through 30 June 2014. Inclusion criteria were adult patients newly prescribed a SC-TNFis with at least three prescriptions and retained on therapy at 24 months.<\/jats:p>\n                    <jats:p>Dosing regimens as per the product monographs were used to compare actual versus expected drug utilisation. The mean possession ratio was used as a marker for adherence. Patients who scored &gt;80% were considered adherent. The average days between units was estimated by taking the total days on therapy and divided by the number of units the patient received.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>4035 patients were included: 683 (16.9%), 1400 (34.7%), 1765 (43.7%) and 187 (4.6%) were treated with GLM, ADA, ETA and CZP, respectively. The proportion of adherent patients in the GLM cohort (n=595\/683, 87%, p&lt;0.0001) was greater compared with ADA (n=1044\/1400, 75%), ETA (n=1285\/1765, 73%) and CZP-treated patients (132\/187, 71%). In addition, the number of patients receiving biological drug at a shorter dosing interval was similar between cohorts, and was 5%, 6%, 12% and 4% in GLM (\u226426 days), ADA (\u226412 days), ETA (\u22646 days) and CZP-treated patients (\u226412 days), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-life administrative database, GLM had better adherence compared with other SC-TNFis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-015872","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T20:10:17Z","timestamp":1505851817000},"page":"e015872","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database"],"prefix":"10.1136","volume":"7","author":[{"given":"Peter","family":"Bhoi","sequence":"first","affiliation":[{"name":"Medical Affairs, Janssen Inc, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[{"name":"Groupe de Recherche en Rhumatologie et Maladies Osseuses, Sainte-Foy, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Tkaczyk","sequence":"additional","affiliation":[{"name":"Medical Affairs, Janssen Inc, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Nantel","sequence":"additional","affiliation":[{"name":"Medical Affairs, Janssen Inc, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Maslova","sequence":"additional","affiliation":[{"name":"Medical Affairs, Janssen Inc, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"2025121600521847000_7.9.e015872.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110207"},{"key":"2025121600521847000_7.9.e015872.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141000"},{"key":"2025121600521847000_7.9.e015872.3","first-page":"2114","article-title":"Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study","volume":"26","author":"Viller","year":"1999","journal-title":"J Rheumatol"},{"key":"2025121600521847000_7.9.e015872.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu358"},{"key":"2025121600521847000_7.9.e015872.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"2025121600521847000_7.9.e015872.6","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.23"},{"key":"2025121600521847000_7.9.e015872.7","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902896386"},{"key":"2025121600521847000_7.9.e015872.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.24114"},{"key":"2025121600521847000_7.9.e015872.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00764.x"},{"key":"2025121600521847000_7.9.e015872.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.02.019"},{"key":"2025121600521847000_7.9.e015872.11","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198808000-00007"},{"key":"2025121600521847000_7.9.e015872.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00268-5"},{"key":"2025121600521847000_7.9.e015872.13","doi-asserted-by":"publisher","DOI":"10.1186\/ar2659"},{"key":"2025121600521847000_7.9.e015872.14","first-page":"449","article-title":"Estimating medication persistency using administrative claims data","volume":"11","author":"Sikka","year":"2005","journal-title":"Am J Manag Care"},{"key":"2025121600521847000_7.9.e015872.15","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200208000-00002"},{"key":"2025121600521847000_7.9.e015872.16","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.clinthera.2011.10.021","article-title":"Impact of medication adherence on health care utilization and productivity: self-reported data from a cohort of postmenopausal women on osteoporosis therapy","volume":"33","author":"Wade","year":"2011","journal-title":"Clin Ther"},{"key":"2025121600521847000_7.9.e015872.17","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181d68978"},{"key":"2025121600521847000_7.9.e015872.18","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.766164"},{"key":"2025121600521847000_7.9.e015872.19","unstructured":"SIMPONI\u00ae\u00a0(Golimumab) Product Monograph. Janssen Inc, 2014:124."},{"key":"2025121600521847000_7.9.e015872.20","unstructured":"CIMZIA\u00ae (Certolizumab pegol) Product Monograph. UCB Canada Inc, 2014:54."},{"key":"2025121600521847000_7.9.e015872.21","doi-asserted-by":"crossref","unstructured":"ENBREL\u00ae (Etanercept) Product Monograph. Amgen Canada Inc, 2015:87.","DOI":"10.1007\/s40278-015-2154-9"},{"key":"2025121600521847000_7.9.e015872.22","unstructured":"HUMIRA\u00ae (Adalimumab) Product Monograph. AbbVie Corp, 2016:141."},{"key":"2025121600521847000_7.9.e015872.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.01.011"},{"key":"2025121600521847000_7.9.e015872.24","doi-asserted-by":"publisher","DOI":"10.1177\/003335491212700102"},{"key":"2025121600521847000_7.9.e015872.25","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181e8bcb0"},{"key":"2025121600521847000_7.9.e015872.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1253-9"},{"key":"2025121600521847000_7.9.e015872.27","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000241107.15133.54"},{"key":"2025121600521847000_7.9.e015872.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.08.018"},{"key":"2025121600521847000_7.9.e015872.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2003.12.012"},{"issue":"4 Suppl 1","key":"2025121600521847000_7.9.e015872.30","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bone.2006.01.150","article-title":"Adherence, patient preference and dosing frequency: understanding the relationship","volume":"38","author":"Reginster","year":"2006","journal-title":"Bone"},{"key":"2025121600521847000_7.9.e015872.31","first-page":"527","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"2025121600521847000_7.9.e015872.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85026-3"},{"key":"2025121600521847000_7.9.e015872.33","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini","year":"2009","journal-title":"Am J Manag Care"},{"key":"2025121600521847000_7.9.e015872.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"2025121600521847000_7.9.e015872.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.406"},{"key":"2025121600521847000_7.9.e015872.36","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0034-3"},{"key":"2025121600521847000_7.9.e015872.37","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.667028"},{"key":"2025121600521847000_7.9.e015872.38","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.786693"},{"key":"2025121600521847000_7.9.e015872.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker404"},{"key":"2025121600521847000_7.9.e015872.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.04.002"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-015872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:52:25Z","timestamp":1765875145000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-015872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,18]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1136\/bmjopen-2017-015872"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-015872","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}